Khiron Life Sciences, an American company with primary operations in Europe and Latin America, reported that they successfully finished the first export of high potency CBD medical cannabis from Colombia and imported it to Peru. The drug would be available later in December.
Khiron has attained GSP certification and partnered with Farmacia Universal, a registered pharmaceutical establishment. Together, they have acquired the necessary medical permit and licenses and GMP certification to sell the CBD products as magistral preparations via pharmacy compounding.
CEO of Khiron, Alvaro Torres, said that Khiron gained the trust for retailing high-quality THC products in the market. The first import into Peru via Colombia is only the beginning of many deals the company wishes to establish and added that they accomplished their motive to become a secure source that delivers genuine medical products to an average consumer while expanding their market growth. Further, he had mentioned that the company has exported over 7,000 units of the products and assured that they would benefit every patient in need.
The company ensured to tick off all the required fields before the shipment and received approval from Peru drug regulatory authority through certification of the potent medical cannabis by DIGEMED. There were many other companies offering drugs of a similar grade but not as potent as CBD products. Hence, Khiron has become a leading company that has expanded the sales of High THC products from Colombia to Peru with reliable prescriptions serving commercial needs. CBD products have been available in Peru since last year, but with low potency. Therefore, Khiron’s high THC products are estimated to serve patients with serious medical conditions.
